Trends, Charts and Exclusive Opinion
Three SmallCaps Close In On 52-Week Highs
ZGEN: RECOTHROM Drug Works Wonders for Burn Patients
MHGC: Package Deal with Virgin America Pushes Stock Higher
ANAD: New 4G Long Term Evolution Products are Introduced
First up this morning is ZymoGenetcis Inc., (ZGEN) http://www.zymogenetics.com/ currently trading in the $5.87 range on a 3-Month average daily trading volume of 359,467 shares. ZGEN was trading in the $3.50 range a year ago. The stock began a rally in May of 09 moving up in small dips and spikes to over $6.50 in Sept. ZGEN cooled off and settled in the $6 level before dropping to $4.50 at the end of Oct. ZGEN then rallied again reaching for the $6 range in Nov and then shooting up in Dec past $7. The stock dipped back to $5 in Feb and has been seeking that $6 level ever since. ZGEN has a 52-week high of $7.31 set on 12-08-09 with current, trailing twelve month revenues of $136+ million.
There are some short-sellers of this stock, but the % ratio will fall into a more normal line as the stock heads for its 52-week high. ZGEN is a long-term (1 Yr) �Buy� consideration for me based on their primary product: RECOTHROM.
Earlier this month, ZGEN announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA. The study marks the first dedicated look at the safety and immunogenicity of ! any stan d-alone thrombin in pediatric surgical patients. The investigators concluded that RECOTHROM did not appear to be associated with any treatment-related adverse events when used as an aid to hemostasis in pediatric patients undergoing synchronous burn wound excision and skin grafting.
A Much Needed, Effective Primary Product
RECOTHROM is an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques; such as sutures, ligatures, or cauteries is ineffective or impractical. ZGEN has a solid drug candidate pipeline and has licensing and collaboration agreements with Merck Serono, Novo Nordisk, Bayer Schering Pharma AG; and Bristol-Myers Squibb.
ZGEN 1-Year
----------------------------------------------------------------------
Sign-Up for Free to Receive Future Commentary and
Trading Alerts on ZGEN, MHGC, and ANAD.
----------------------------------------------------------------------
Next up this morning is Morgans Hotel Group (MHGC) http://www.morganshotelgroup.com/ currently trading in the $5.58 range on a 3-Month average daily trading volume of 190,126 shares. MHGC ! was trad ing in the $3 range a year ago. In April, it rose past $5, but settled back to the $3.50 level by July 09. MHGC then rallied past $5.50 in Aug, then to $6.50 in Sept. MHGC fell in Oct to $3. Steep. But the stock rallied and has been climbing ever since into its current range. MHGC has a 52-week high of $6.50 set on 09-22-09 with current trailer twelve month revenues of $232+ million. There are also a lot of short-sellers of this stock, but they too will decline as MHGC reaches towards its 52-week high (approximately 90 cents away on the spread). MHGC is a long-term �Buy� consideration for me. I like the Company�s �activism� in bringing in customers.
10-Days ago, MHGC announced a partnership with Virgin America where guests at MHGC hotels will earn frequent flyer points on Virgin. As the travel industry recovers from the recession; consumers are looking for deals just like that. MHGC owns and manages Morgans, Royalton, and Hudson hotels in New York, Delano South Beach, Mondrian South Beach, and Shore Club hotels in Miami. MHGC also owns the Mondrian in Los Angeles, the Clift in San Francisco, the Mondrian in Scottsdale, St. Martins Lane and Sanderson hotels in London, the Hard Rock hotel and casino in Las Vegas, and Ames hotel in Boston. As of December 31, 2009, MHGC owned, or partially owned, and managed a portfolio of 13 luxury hotel properties comprising approximately 4,700 rooms.
Finally this morning is Anadigics Inc., (ANAD) http://www.anadigics.com/ currently trading in the $4.86 range on a 3-Month average daily trading volume of 630,344 shares.
ANAD was trading in the $2 ! range a year ago. The stock jumped past $4.50 in June of 09 and then went through a series of dips and spikes culminating in mid-Sept at a $5 price level. ANAD then retreated in the next 2-Months back to the $3 range before rallying and spiking past $4.50 in Jan 2010. ANAD dipped in Feb by a buck, but has roared back this month towards its high. ANAD has a 52-week high of $5.21 set on 09-21-09 with current trailing twelve month revenues of $140+ million.
�ANAD is a long-term �Buy� consideration for me because of the Company�s cutting edge 4G Long Term Evolution (LTE) product mix. Earlier this month, ANAD introduced a new set of multi-mode, high-performance power amplifiers designed for wireless datacards and handsets for the rapidly emerging 4G Long Term Evolution (LTE) and advanced HSPA technologies.
These new single-band PAs are built using the fourth generation of ANADIGICS' patented HELP� (High-Efficiency-at-Low-Power) technology to deliver exceptional performance to customers making USB modules and new generation handsets based on the LTE standard. Analyst firm Gartner states that LTE is on track to become one of the dominant 4G technologies for mobile broadband within this decade. By 2015, LTE coverage is expected to reach at least 50 percent of all mobile subscribers in the United States and Western Europe.
If ! you'd li ke to receive further updates and any changes in our opinions of ZGEN, MHGC, and ANAD,�be sure to Sign-Up for the SCN Newsletter today! It's FREE.�
Related Articles:DrStockPick.com Stock Report! 8/20/09, ETAK, DRJ, PWOIF, HI, AEXP, BCO
Greek Default: Good News?
Tags: 2013 Financials Stocks ,AEXP ,BCO ,Best Stocks To Own For 2013 ,Best Stocks To Own In 2013 ,DRJ ,ETAK ,HI ,PWOIF ,Best China Stocks 2012
No comments:
Post a Comment